All publications related to the CUREiHUS study are listed here:
Twenty aHUS patients are described who received eculizumab for a short period of time after which therapy is withdrawn. This study shows a restrictive treatment regimen is feasable. Moreover, appears even safe and (cost)effective.
This study provides essential insight in optimization of eculizumab dosing schemes and lessening of therapy burden for the patients and cost of the treatment.
The PESaM Questionnaire is an add-on study of the CUREiHUS study to assess patient experience and satisfaction with eculizumab.
The serological anti-O157 LPS assay clearly makes a positive contribution when used in combination with standard fecal diagnostic tests to diagnose STEC-HUS and should be incorporated in clinical practice.